Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.77 EUR
−41.72 M EUR
24.88 M EUR
53.08 M
About Zevra Therapeutics, Inc.
Sector
CEO
Neil F. McFarlane
Headquarters
Celebration
Website
Founded
2006
FIGI
BBG009F52BY8
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 1GDA is 8.15 EUR — it has decreased by −1.21% in the past 24 hours. Watch ZEVRA THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange ZEVRA THERAPEUTICS INC stocks are traded under the ticker 1GDA.
1GDA stock has risen by 1.88% compared to the previous week, the month change is a −1.81% fall, over the last year ZEVRA THERAPEUTICS INC has showed a 42.98% increase.
We've gathered analysts' opinions on ZEVRA THERAPEUTICS INC future price: according to them, 1GDA price has a max estimate of 24.18 EUR and a min estimate of 14.51 EUR. Watch 1GDA chart and read a more detailed ZEVRA THERAPEUTICS INC stock forecast: see what analysts think of ZEVRA THERAPEUTICS INC and suggest that you do with its stocks.
1GDA reached its all-time high on Mar 3, 2021 with the price of 18.04 EUR, and its all-time low was 3.02 EUR and was reached on Jul 26, 2007. View more price dynamics on 1GDA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
1GDA stock is 1.23% volatile and has beta coefficient of 1.06. Track ZEVRA THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is ZEVRA THERAPEUTICS INC there?
Today ZEVRA THERAPEUTICS INC has the market capitalization of 441.29 M, it has increased by 2.17% over the last week.
Yes, you can track ZEVRA THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
ZEVRA THERAPEUTICS INC is going to release the next earnings report on Feb 28, 2025. Keep track of upcoming events with our Earnings Calendar.
1GDA earnings for the last quarter are −0.62 EUR per share, whereas the estimation was −0.37 EUR resulting in a −67.69% surprise. The estimated earnings for the next quarter are −0.38 EUR per share. See more details about ZEVRA THERAPEUTICS INC earnings.
ZEVRA THERAPEUTICS INC revenue for the last quarter amounts to 3.32 M EUR, despite the estimated figure of 4.37 M EUR. In the next quarter, revenue is expected to reach 8.62 M EUR.
1GDA net income for the last quarter is −29.84 M EUR, while the quarter before that showed −18.60 M EUR of net income which accounts for −60.42% change. Track more ZEVRA THERAPEUTICS INC financial stats to get the full picture.
No, 1GDA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 9, 2025, the company has 69.00 employees. See our rating of the largest employees — is ZEVRA THERAPEUTICS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ZEVRA THERAPEUTICS INC EBITDA is −72.51 M EUR, and current EBITDA margin is −176.97%. See more stats in ZEVRA THERAPEUTICS INC financial statements.
Like other stocks, 1GDA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ZEVRA THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ZEVRA THERAPEUTICS INC technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ZEVRA THERAPEUTICS INC stock shows the buy signal. See more of ZEVRA THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.